매크로 컨텍스트

테마

ADC & Antibody-Drug Conjugates

핵심 동인

  • ALT-B4 platform multi-big pharma licensing deals signed
  • Surging ADC subcutaneous conversion demand
  • Keytruda SC conversion clinical in progress (Merck-directed)
  • Technology licensing milestones and royalties long-term revenue structure

리스크

  • Halozyme hyaluronidase patent competition
  • Technology licensing milestone delays
  • Potential ALT-B4 immunogenicity issues
  • Clinical stage uncertainty

애널리스트 컨센서스

최저 250,000 KRW최고 580,000 KRW
현재가컨센서스 목표가

2026. 6. 16. 기준

증권사애널리스트목표가투자의견
투자 기간: 12개월

모니터링 트리거

핵심 지표

  • Technology licensing milestone receipt schedule
  • ALT-B4 clinical pipeline advancement
  • Keytruda SC conversion clinical results
  • New big pharma licensing agreements

리뷰 트리거

  • Major licensing agreement termination
  • ALT-B4 immunogenicity issue in clinical trials
  • Halozyme patent litigation loss

무효화 조건

  • ALT-B4 platform technology competitiveness lost
  • 3+ big pharma licensing agreements terminated
  • Alternative SC conversion technology emerges

노트 타임라인

진입
2026. 2. 25. · NewMoneyMoves AI

Platform value validated through multiple global big pharma licensing deals including Merck, Roche, and BMS. Keytruda SC conversion is the biggest catalyst. Long-term growth structure based on big pharma milestones and royalties.

Related ETFs

ETFs covering the same theme as 196170.KS — alternatives when direct holding is constrained or diversification is preferred

All ETFs

Comments

생성: 2026. 2. 25.수정: 2026. 2. 25.가격 기준: 2026. 6. 16.